Antimicrobial stewardship programs (ASPs) can be expanded to the outpatient setting to serve as a first line of defense against coronavirus disease 19 (COVID-19) hospitalizations and to reduce the burden on emergency departments and acute-care hospitals. Given the numerous emergency use authorizations of monoclonal antibodies and oral antivirals, ASPs possess the expertise and leadership to direct ambulatory COVID-19 initiatives and transform it into a predominantly outpatient illness. In this review, we summarize the critical role and benefits of an ASP-championed ambulatory COVID-19 therapeutics program.
|Original language||English (US)|
|Journal||Antimicrobial Stewardship and Healthcare Epidemiology|
|State||Published - Apr 29 2022|
ASJC Scopus subject areas
- Infectious Diseases
- Microbiology (medical)